SCHEDULE 13G/A: BlackRock, Inc. Discloses 5.1% Passive Stake in Ultragenyx Pharmaceutical Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Ultragenyx Pharmaceutical Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 4,820,931 shares of common stock in Ultragenyx Pharmaceutical Inc.
• This represents 5.1% of the total outstanding common stock of Ultragenyx Pharmaceutical Inc.
• The filing is an Amendment No. 2 to a previous Schedule 13G, indicating an update to their beneficial ownership position.
• BlackRock, Inc. holds sole voting power over 4,669,755 shares and sole dispositive power over 4,820,931 shares.
• The shares were acquired and are held in the ordinary course of business and are not for the purpose of changing or influencing control of the issuer.
• BlackRock Fund Managers Ltd, a subsidiary of BlackRock, Inc., is specifically identified as an entity that beneficially owns 5% or greater of the outstanding shares of Ultragenyx Pharmaceutical Inc.

Sentiment

Score: 5

Explanation: The document is a neutral, factual regulatory filing disclosing beneficial ownership. It contains no positive or negative operational or financial news about the issuer, Ultragenyx Pharmaceutical Inc., nor does it imply any significant change in BlackRock's investment stance beyond routine adjustments.

Positives

• BlackRock, a major institutional investor, maintains a significant stake, indicating continued confidence in Ultragenyx Pharmaceutical Inc.
• The ownership is passive, suggesting no immediate intent to influence company control, which can provide stability for current management and strategy.

Risks

• The document explicitly states that the shares are not held for the purpose of changing or influencing the control of the issuer, which means there is no indication of potential activist involvement that might push for strategic changes.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Ultragenyx Pharmaceutical Inc.'s future performance or BlackRock's investment strategy beyond the passive nature of the current holding.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure by a major asset manager, BlackRock, Inc., regarding its passive investment in a biotechnology company, Ultragenyx Pharmaceutical Inc. It reflects standard institutional portfolio management and does not indicate any specific industry trends or competitive shifts.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of beneficial ownership by a large institutional investor. It does not contain performance metrics or operational data that would allow for a direct comparison to industry-specific benchmarks or competitor results.
• The 5.1% stake is a standard reporting threshold for passive investors, and BlackRock's filing is consistent with typical compliance requirements for large asset managers.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which can offer some stability and validation of the company's investment appeal, but no direct operational impact.

Key Dates

Keywords

Ultragenyx Pharmaceutical Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, UGNX, Biotechnology, Pharmaceuticals